(-0.03%) 5 477.00 points
(-0.07%) 38 791 points
(0.02%) 19 925 points
(0.25%) $80.53
(1.33%) $2.83
(0.16%) $2 332.70
(-0.33%) $29.30
(-0.22%) $968.80
(0.01%) $0.932
(-0.15%) $10.64
(0.06%) $0.788
(-1.86%) $86.80
Live Chart Being Loaded With Signals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary...
Stats | |
---|---|
Šios dienos apimtis | 296 322 |
Vidutinė apimtis | 594 359 |
Rinkos kapitalizacija | 110.18M |
EPS | $-0.240 ( Q2 | 2023-08-14 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.694 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0990 (8.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2021-01-24 | Klein Christopher | Sell | 9 605 | Ordinary Shares |
2020-05-20 | Cowan Gregory L | Buy | 38 716 | Ordinary Shares |
2020-05-21 | Cowan Gregory L | Sell | 11 112 | Ordinary Shares |
2020-01-28 | Schaub James | Sell | 9 197 | Ordinary Shares |
2019-01-24 | Weiss Fred G | Buy | 34 403 | Ordinary Shares |
INSIDER POWER |
---|
0.00 |
Last 6 transactions |
Buy: 177 968 | Sell: 29 914 |
Tūris Koreliacija
Osmotica Pharmaceuticals Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Osmotica Pharmaceuticals Koreliacija - Valiuta/Žaliavos
Osmotica Pharmaceuticals Finansinės ataskaitos
Annual | 2022 |
Pajamos: | $49.72M |
Bruto pelnas: | $40.27M (80.98 %) |
EPS: | $-0.580 |
FY | 2022 |
Pajamos: | $49.72M |
Bruto pelnas: | $40.27M (80.98 %) |
EPS: | $-0.580 |
FY | 2020 |
Pajamos: | $177.88M |
Bruto pelnas: | $103.40M (58.13 %) |
EPS: | $-1.520 |
FY | 2019 |
Pajamos: | $240.03M |
Bruto pelnas: | $128.40M (53.49 %) |
EPS: | $-5.17 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Osmotica Pharmaceuticals
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.